Results of univariate logistic regression for odds of development of PTS
| Explanatory variable . | OR for PTS (95% CI) . | P . |
|---|---|---|
| Thrombolytic therapy | 0.09 (0.01-0.66) | .02 |
| Age, y | 1.2 (1.0-1.4) | .10 |
| Lag to therapy | 1.1 (0.95-1.3) | .20 |
| DVT extent (no. venous segments involved) | 1.1 (0.57-2.2) | .76 |
| Central venous catheter | 0.30 (0.04-2.2) | .23 |
| FVIII | 0.99 (0.97-1.0) | .39 |
| D-dimer | 1.0 (1.0-1.0) | .37 |
| Genetic thrombophilia | 0.30 (0.05-1.9) | .21 |
| Lupus anticoagulant | 0.72 (0.11-4.6) | .73 |
| APA syndrome | 1.4 (0.18-11.1) | .73 |
| Acquired thrombophilia | 0.88 (0.14-5.6) | .89 |
| Thrombus resolution | 0.09 (0.01-0.96) | .046 |
| Explanatory variable . | OR for PTS (95% CI) . | P . |
|---|---|---|
| Thrombolytic therapy | 0.09 (0.01-0.66) | .02 |
| Age, y | 1.2 (1.0-1.4) | .10 |
| Lag to therapy | 1.1 (0.95-1.3) | .20 |
| DVT extent (no. venous segments involved) | 1.1 (0.57-2.2) | .76 |
| Central venous catheter | 0.30 (0.04-2.2) | .23 |
| FVIII | 0.99 (0.97-1.0) | .39 |
| D-dimer | 1.0 (1.0-1.0) | .37 |
| Genetic thrombophilia | 0.30 (0.05-1.9) | .21 |
| Lupus anticoagulant | 0.72 (0.11-4.6) | .73 |
| APA syndrome | 1.4 (0.18-11.1) | .73 |
| Acquired thrombophilia | 0.88 (0.14-5.6) | .89 |
| Thrombus resolution | 0.09 (0.01-0.96) | .046 |
Thrombolytic therapy is compared to standard anticoagulation. PTS was uniformly assessed at 18-24 months after diagnosis of deep venous thrombosis. Lag to therapy represents time from symptom onset to institution of antithrombotic therapy. Acquired thrombophilia excludes FVIII activity, D-dimer concentration, and the presence of the lupus anticoagulant, which are given separately. Thrombus resolution indicates ≥90% thrombus resolution as documented radiologically at one year after diagnosis of deep venous thrombosis.
PE indicates pulmonary embolism; FVIII, factor VIII activity; APA, antiphospholipid antibody.